Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology.


Journal

Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041

Informations de publication

Date de publication:
05 2019
Historique:
received: 01 01 2019
accepted: 08 02 2019
revised: 06 02 2019
pubmed: 26 2 2019
medline: 10 7 2020
entrez: 27 2 2019
Statut: ppublish

Résumé

Deposition of α-synuclein into Lewy bodies and Lewy neurites is the hallmark of Parkinson's disease (PD). It is hypothesized that α-synuclein pathology spreads by a "prion-like" mechanism (i.e., by seeded aggregation or templated misfolding). Therefore, various extracellular α-synuclein conformers and/or posttranslational modifications may serve as biomarkers of disease or potential targets for novel interventions. To explore whether the antibody repertoires of PD patients contain anti-α-synuclein antibodies that can potentially be used as markers or immunotherapy, we interrogated peripheral IgG

Identifiants

pubmed: 30805666
doi: 10.1007/s00401-019-01974-5
pii: 10.1007/s00401-019-01974-5
pmc: PMC6482120
doi:

Substances chimiques

Antibodies 0
SNCA protein, human 0
alpha-Synuclein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

825-836

Références

Nat Rev Neurosci. 2013 Jan;14(1):38-48
pubmed: 23254192
J Neurosci. 2010 Mar 3;30(9):3184-98
pubmed: 20203178
J Neurosci. 2012 Sep 26;32(39):13454-69
pubmed: 23015436
Immunol Lett. 2015 Nov;168(1):80-8
pubmed: 26386375
J Parkinsons Dis. 2016;6(1):39-51
pubmed: 27003784
J Neuroimmunol. 2011 Apr;233(1-2):221-7
pubmed: 21239064
Comb Chem High Throughput Screen. 2009 Sep;12(8):791-800
pubmed: 19758119
Mov Disord. 2017 Feb;32(2):211-218
pubmed: 27886407
Mov Disord. 2011 Aug 1;26(9):1593-604
pubmed: 21618611
Neurology. 2013 Jan 8;80(2):169-75
pubmed: 23255825
Eur J Neurosci. 2010 Aug;32(3):409-22
pubmed: 20704592
Mov Disord. 2016 Feb;31(2):214-24
pubmed: 26260853
PLoS One. 2014 Dec 03;9(12):e114566
pubmed: 25470145
PLoS One. 2011 Apr 29;6(4):e19338
pubmed: 21559417
Sci Rep. 2013;3:2540
pubmed: 23985836
J Neurosci. 2014 Jul 9;34(28):9441-54
pubmed: 25009275
Nat Med. 2015 Jul;21(7):802-7
pubmed: 26099047
Nat Genet. 2010 Sep;42(9):781-5
pubmed: 20711177
Cell. 2013 Jul 3;154(1):103-17
pubmed: 23827677
Neuron. 2005 Jun 16;46(6):857-68
pubmed: 15953415
Neuroimmunomodulation. 2012;19(6):334-42
pubmed: 22986484
Neurology. 2008 May 13;70(20):1916-25
pubmed: 18474848
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2634-E2643
pubmed: 29487216
Mol Neurobiol. 2013 Apr;47(2):509-24
pubmed: 22923347
PLoS One. 2012;7(12):e52285
pubmed: 23284971
Acta Neuropathol Commun. 2018 May 31;6(1):43
pubmed: 29855358
J Neurochem. 2007 May;101(3):749-56
pubmed: 17448146
Nat Med. 2017 Feb 7;23(2):1-13
pubmed: 28170377
Acta Neuropathol. 2017 May;133(5):767-783
pubmed: 28341999
Acta Neuropathol Commun. 2018 Jul 12;6(1):59
pubmed: 30001207
Nature. 2017 Jun 29;546(7660):656-661
pubmed: 28636593
PLoS One. 2013 May 31;8(5):e64649
pubmed: 23741358
Sci STKE. 2007 Jun 05;2007(389):pl2
pubmed: 17551170
Ann Hum Genet. 2010 Mar;74(2):97-109
pubmed: 20070850
Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2162-7
pubmed: 15684072
Front Aging Neurosci. 2014 Jul 15;6:169
pubmed: 25076905
FEBS Lett. 1998 Nov 27;440(1-2):71-5
pubmed: 9862428
Acta Neuropathol Commun. 2017 Jan 13;5(1):7
pubmed: 28086964
Am J Hum Genet. 2013 Nov 7;93(5):984-93
pubmed: 24183452
NPJ Parkinsons Dis. 2015;1:
pubmed: 27148593
Cell Stem Cell. 2018 Jul 05;23(1):123-131.e6
pubmed: 29979986
Cell Rep. 2014 Jun 26;7(6):2054-65
pubmed: 24931606
Neurology. 1987 May;37(5):754-60
pubmed: 3033544

Auteurs

Xinyi Li (X)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.

Wouter Koudstaal (W)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333 CN, Leiden, The Netherlands.
Lucidity Biomedical Consulting, Calle Emir 11, 18006, Granada, Spain.

Lauren Fletcher (L)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.

Martha Costa (M)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.

Margot van Winsen (M)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333 CN, Leiden, The Netherlands.

Berdien Siregar (B)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333 CN, Leiden, The Netherlands.

Hanna Inganäs (H)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333 CN, Leiden, The Netherlands.

Julie Kim (J)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.

Elissa Keogh (E)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.

Jeremy Macedo (J)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.

Trevin Holland (T)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.

Stuart Perry (S)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.

Frederique Bard (F)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.

Jeroen J Hoozemans (JJ)

Department of Pathology, Amsterdam Neuroscience, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Jaap Goudsmit (J)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333 CN, Leiden, The Netherlands.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, 02115, USA.
Department of Neurology, Amsterdam Neuroscience, Academic Medical Center, Meidreefberg 9, 1105 AZ, Amsterdam, The Netherlands.

Adrian Apetri (A)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333 CN, Leiden, The Netherlands.

Gabriel Pascual (G)

Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA. GPascual@its.jnj.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH